35 results about "Glial scar" patented technology

The invention belongs to the technical field of medicines and particularly relates to application of a compound shown in a formula (1) shown in the description to the preparation of a drug for preventing and / or treating nerve damage. The compound can reduce pro-inflammatory cytokines, lower the apoptosis level, promote the survival of neurons and inhibit the formation of glial scars after damage, and has a significant protecting effect on motion function recovery.

The present invention is based on the capacity of the Olfactory Ensheathing Glia (OEG) to foster axonal regeneration in the adult mammalian central nervous system (CNS). This specific capacity is probably due to a combination of several factors, such as the molecular composition of cellular membrane and / or the capacity to secrete some molecules; combined with the capacity to reduce glial scar and accompany new growing axon in the damaged CNS. We have developed immortalised cell lines from primary human OEGs. The cells were cultured from post-mortem human tissue from donors and immortalised using a reversible system. Some of these OEG human clonal cell lines were selected by their ability to promote axonal regeneration from adult rat retinal ganglion neurons in a similar fashion to primary OEGs. These cell lines, alone or in pharmaceutical compositions comprising these cells, may be used to repair neuronal damage in the CNS.

The invention provides a preparation method of a human oligodendrocyte precursor cell inhibiting nerve secondary. Specifically, the method includes: constructing a virus expression vector of two glial growth factors, conducting cotransfection of a human oligodendrocyte precursor cell to prepare the human oligodendrocyte precursor cell, which can achieve high expression of the two glial growth factors, i.e. a growth related factor 43 and a glial growth factor 2, give play to the combined action of the two to promote oligodendrocyte repair, and inhibit nerve secondary injury caused by proliferative response and glial scar formation after oligodendrocyte injury. Also, the proliferation and differentiation ability of oligodendrocyte precursor cell itself is also utilized to participate in nerve function repair, and no tumorigenesis exists. The invention also provides a kit for preparation of the human oligodendrocyte precursor cell inhibiting nerve secondary. The human oligodendrocyte precursor cell provided by the invention has very good therapeutic effect on nervous system diseases.

The invention provides miR-124-containing glioma cell exosomes, a preparation method and application thereof, and belongs to the technical field of central nervous system damage repairing drugs. A method for preparing glioma cell exosomes containing miR-124, the supernatant obtained by culturing a glioma cell line is subjected to solid-liquid separation; the separated exosomes and miR-124 are mixed and incubated together to obtain a Glioma cell exosomes of miR‑124. The exosomes prepared above can effectively bind to cholesterol-modified miR-124 and be absorbed by reactive astrocytes, significantly increase the expression of miR-124 in reactive astrocytes, and inhibit astrocytes. Activation and scarring. Therefore, the present invention also provides the application of miR-124-containing glioma cell exosomes in the preparation of a drug for inhibiting astrocyte activation and / or glial scar formation, thereby treating central nervous system injury diseases.

The invention provides application of nafamostat in preparation of a medicament for treating spinal cord injury. The nafamostat is applied to therapeutic intervention of the spinal cord injury, and experiments show that the nafamostat can reduce apoptosis of cells, promote survival of neurons, inhibit formation of glial scars and remarkably improve the BBB score of a treated animal. Compared with a methylprednisolone medicament applied clinically at present, the nafamostat has the advantages of wider administration window, more lasting treatment effect and better long-term effect.

The present invention falls within the field of medical technology, and in particular relates to the use of a compound as shown in formula (I). In particular, the present invention relates to the use of the compound as shown in formula (I) in the preparation of a pharmaceutical composition for preventing and / or treating a nerve injury, or relieving a nerve injury-associated symptom, and further relates to the use thereof in the preparation of a healthcare product for protecting an injured nerve and / or improving motor function. After a nerve injury has occurred, the compound can reduce the production of pro-inflammatory cytokine, decrease the level of apoptosis, promote the survival of neuron, inhibit the formation of glial scar, and has a significant effect in promoting the recovery of motor function.

The invention belongs to the technical field of cell biology. The invention provides a method for constructing an in vitro glial scar formation model, which comprises purifying the purified cerebellar (spinal) membrane fibroblasts and astrocytes in a certain quantitative ratio. Planted in adjacent small chambers on chamber slides, culture medium was added; when the cells adhered to the wall, the partitions between small chambers were removed, and the culture was continued; when brain (spinal) membrane fibroblasts and When these two types of cells grow and approach each other, astrocytes use a sharp instrument to make mechanical scratches at the junction of the two types of cells to damage the cells, eventually forming a glial-like scar structure. The in vitro glial scar formation model obtained by the present invention can better simulate the whole process of in vivo glial scar formation, and the corresponding morphological structure of the glial scar and the changes of related cell biology and molecular biology appear, which is called glial scar formation. Mechanism studies and related therapeutic studies provide experimental models at the cellular level in vitro.

The invention provides a method for activating astrocytes by using surface microstructures, which belongs to the field of cell culture technology. The specific steps are: (1) obtaining a PDMS cell culture surface with uneven microstructures; The subcultured glial cells are the activation objects. After the cells grow to the cell fusion, the cells are digested with 0.25% trypsin to make a cell suspension. (3) Add the cell suspension to the surface of the microstructure. After the cells adhere to the wall, Cultured for 1-14 days; (4) The astrocytes obtained by the above method were identified to show a series of activation performances such as EMT transformation, enhanced cell stemness, and enhanced glucose transport. The advantage of the present invention is that glial cells can be activated by using the physical microstructure on the surface of the culture, and glial scars caused by reactive hyperplasia of glial cells can be avoided. The invention has broad application prospects in the treatment of nervous system damage and degenerative diseases.